<?xml version='1.0' encoding='utf-8'?>
<document id="21220503"><sentence text="Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial."><entity charOffset="11-21" id="DDI-PubMed.21220503.s1.e0" text="patupilone" /></sentence><sentence text="Patupilone is a novel microtubule-targeting cytotoxic agent, which exerts its antitumor effect through microtubule stabilization"><entity charOffset="0-10" id="DDI-PubMed.21220503.s2.e0" text="Patupilone" /></sentence><sentence text=" Pharmacokinetics, pharmacodynamics, and safety of warfarin when administered concomitantly with patupilone were investigated, and antitumor activity was assessed"><entity charOffset="97-107" id="DDI-PubMed.21220503.s3.e0" text="patupilone" /></sentence><sentence text=" This was a phase I, two-center, drug-drug interaction study" /><sentence text=" In the core phase of the study, treatment consisted of warfarin 20 mg orally (days 1 and 29) and patupilone 10 mg/m(2) i"><entity charOffset="98-108" id="DDI-PubMed.21220503.s5.e0" text="patupilone" /></sentence><sentence text="v" /><sentence text=" (days 8 and 29)" /><sentence text=" Patients benefiting from patupilone treatment continued treatment every 3 weeks (extension phase) until progression of disease, death, or unacceptable toxicity"><entity charOffset="26-36" id="DDI-PubMed.21220503.s8.e0" text="patupilone" /></sentence><sentence text=" Seventeen patients were treated (core phase, 17; extension, 9)" /><sentence text=" The geometric mean ratios (comedication/monotherapy) for C(max) and area under the curve(0-168) of warfarin were near unity and their 90% confidence intervals were within the equivalence limits of 0" /><sentence text="80 and 1" /><sentence text="25" /><sentence text=" The half-life, plasma clearance, and International Normalized Ratio (INR) of warfarin were not affected by patupilone coadministration" /><sentence text=" The most common adverse events were diarrhea, nausea, vomiting, abdominal pain, anorexia, dehydration, asthenia, and peripheral neuropathy" /><sentence text=" Five (29" /><sentence text="4%) patients experienced grade 3 study drug-related adverse events (diarrhea, 17" /><sentence text="6%; increased INR, 11" /><sentence text="8%; dehydration, 5" /><sentence text="9%; and neutropenia, 5" /><sentence text="9%)" /><sentence text=" One patient with triple-negative breast cancer (estrogen receptor, progesterone receptor, and HER2/neu negative) had a partial response (35% decrease in tumor measurements by Response Evaluation Criteria in Solid Tumors), and 11 had stable disease for 6 weeks or more (â‰¥12 weeks, 6 patients)"><entity charOffset="49-57" id="DDI-PubMed.21220503.s21.e0" text="estrogen" /><entity charOffset="68-80" id="DDI-PubMed.21220503.s21.e1" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.21220503.s21.e0" e2="DDI-PubMed.21220503.s21.e0" /><pair ddi="false" e1="DDI-PubMed.21220503.s21.e0" e2="DDI-PubMed.21220503.s21.e1" /></sentence><sentence text=" The pharmacokinetics and pharmacodynamics of warfarin were not affected by patupilone coadministration, suggesting that patupilone has no clinically relevant effect on CYP2C9 metabolism"><entity charOffset="121-131" id="DDI-PubMed.21220503.s22.e0" text="patupilone" /></sentence><sentence text=" Patupilone showed antitumor activity in triple-negative breast cancer"><entity charOffset="1-11" id="DDI-PubMed.21220503.s23.e0" text="Patupilone" /></sentence><sentence text="" /></document>